Last reviewed · How we verify
Dorzolamide-timolol and latanoprost
This combination reduces intraocular pressure through three mechanisms: dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production, timolol blocks beta-adrenergic receptors to reduce aqueous humor secretion, and latanoprost increases uveoscleral outflow of aqueous humor.
This combination reduces intraocular pressure through three mechanisms: dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production, timolol blocks beta-adrenergic receptors to reduce aqueous humor secretion, and latanoprost increases uveoscleral outflow of aqueous humor. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Dorzolamide-timolol and latanoprost |
|---|---|
| Also known as | Eliptic Ofteno PF®, Gaap Ofteno PF® |
| Sponsor | Laboratorios Sophia S.A de C.V. |
| Drug class | Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog |
| Target | Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dorzolamide and timolol work synergistically on aqueous humor production while latanoprost enhances drainage through the uveoscleral pathway. This triple mechanism provides additive intraocular pressure reduction compared to individual agents. The combination is designed for patients with glaucoma or ocular hypertension requiring multi-drug therapy.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation/burning
- Blurred vision
- Conjunctival hyperemia
- Eyelash growth/darkening
- Iris pigmentation changes
- Systemic beta-blocker effects (bradycardia, fatigue)
Key clinical trials
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? (PHASE4)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
- Circadian Rhythms of Aqueous Humor Dynamics in Humans (PHASE2)
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma (PHASE4)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: